Roche Holding ROP 1.21%increase; up pointing triangle said a drug candidate showed better potential than existing therapies in a late-stage study with patients with a type of advanced lung cancer who had been previously treated.
The Swiss drugmaker said Thursday that its experimental drug, divarasib, met its primary and key secondary objectives in a head-to-head clinical trial that compared it against approved treatments Amgen’s AMGN 1.51%increase; up pointing triangle Lumakras and Mirati Therapeutics’s Krazati.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8